Cargando…

Distinct Metabolomic Signatures in Preclinical and Obstructive Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy (HCM) is a common inherited heart disease with poor risk prediction due to incomplete penetrance and a lack of clear genotype–phenotype correlations. Advanced imaging techniques have shown altered myocardial energetics already in preclinical gene variant carriers. To dete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuldt, Maike, van Driel, Beau, Algül, Sila, Parbhudayal, Rahana Y., Barge-Schaapveld, Daniela Q. C. M., Güçlü, Ahmet, Jansen, Mark, Michels, Michelle, Baas, Annette F., van de Wiel, Mark A., Nieuwdorp, Max, Levin, Evgeni, Germans, Tjeerd, Jans, Judith J. M., van der Velden, Jolanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616419/ https://www.ncbi.nlm.nih.gov/pubmed/34831173 http://dx.doi.org/10.3390/cells10112950

Ejemplares similares

Metabolomics in Severe Aortic Stenosis Reveals Intermediates of Nitric Oxide Synthesis as Most Distinctive Markers
por: van Driel, Beau Olivier, et al.
Publicado: (2021)

Increased Myocardial Oxygen Consumption Precedes Contractile Dysfunction in Hypertrophic Cardiomyopathy Caused by Pathogenic TNNT2 Gene Variants
por: Parbhudayal, Rahana Y., et al.
Publicado: (2020)

Regional myocardial function at preclinical disease stage of hypertrophic cardiomyopathy in female gene variant carriers
por: Parbhudayal, Rahana Y., et al.
Publicado: (2021)

Blood‐based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta‐analysis
por: Jansen, Mark, et al.
Publicado: (2022)

Myocardial adaptation after surgical therapy differs for aortic valve stenosis and hypertrophic obstructive cardiomyopathy
por: Parbhudayal, Rahana Y., et al.
Publicado: (2019)

In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
por: Brouwer, Wessel P, et al.
Publicado: (2014)

Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants
por: Jansen, Mark, et al.
Publicado: (2023)

The effect of inhibition of the Na(+)/H(+) exchanger on the development of hypertrophy in hypertrophic cardiomyopathy
por: Brouwer, Wessel P, et al.
Publicado: (2011)

Increased left ventricular torsion in hypertrophic cardiomyopathy mutation carriers with normal wall thickness
por: Rüssel, Iris K, et al.
Publicado: (2011)

Protein Quality Control Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy
por: Dorsch, Larissa M., et al.
Publicado: (2019)

Sex-Related Differences in Protein Expression in Sarcomere Mutation-Positive Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance
por: Germans, Tjeerd, et al.
Publicado: (2010)

Scientists on the spot: Relaxing the heart in hypertrophic cardiomyopathy
por: Gladka, Monika M, et al.
Publicado: (2023)

Molecular autopsy
por: van Driel, B., et al.
Publicado: (2018)

The microtubule signature in cardiac disease: etiology, disease stage, and age dependency
por: Algül, Sıla, et al.
Publicado: (2023)

Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
por: van Velzen, H. G., et al.
Publicado: (2019)

Life-long tailoring of management for patients with hypertrophic cardiomyopathy: Awareness and decision-making in changing scenarios
por: Michels, M., et al.
Publicado: (2016)

CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation
por: Papavassiliu, Theano, et al.
Publicado: (2009)

Strength of patient cohorts and biobanks for cardiomyopathy research
por: de Boer, R. A., et al.
Publicado: (2020)

Feature tracking compared with tissue tagging measurements of segmental strain by cardiovascular magnetic resonance
por: Wu, LiNa, et al.
Publicado: (2014)

Mutation location of HCM-causing troponin T mutations defines the degree of myofilament dysfunction in human cardiomyocytes
por: Schuldt, Maike, et al.
Publicado: (2021)

Sex-specific cardiac remodeling in early and advanced stages of hypertrophic cardiomyopathy
por: Nijenkamp, Louise L. A. M., et al.
Publicado: (2020)

ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study)
por: Güçlü, A., et al.
Publicado: (2013)

Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration
por: Nollet, Edgar E, et al.
Publicado: (2023)

Extra energy for hearts with a genetic defect: ENERGY trial
por: van Driel, B. O., et al.
Publicado: (2019)

Correction to: Extra energy for hearts with a genetic defect: ENERGY trial
por: van Driel, B. O., et al.
Publicado: (2019)

Untying the knot: protein quality control in inherited cardiomyopathies
por: Dorsch, Larissa M., et al.
Publicado: (2018)

BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status
por: Jansen, M., et al.
Publicado: (2021)

Unraveling the Genotype‐Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity‐Related Cardiac Defects as a Major Disease Modifier
por: Nollet, Edgar E., et al.
Publicado: (2020)

Genotype‐specific pathogenic effects in human dilated cardiomyopathy
por: Bollen, Ilse A. E., et al.
Publicado: (2017)

End‐diastolic force pre‐activates cardiomyocytes and determines contractile force: role of titin and calcium
por: Najafi, Aref, et al.
Publicado: (2019)

Prognostic significance of anterior mitral valve leaflet length in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
por: van Velzen, Hannah G., et al.
Publicado: (2018)

Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations
por: Pei, J., et al.
Publicado: (2021)

Transcriptional bursts and heterogeneity among cardiomyocytes in hypertrophic cardiomyopathy
por: Burkart, Valentin, et al.
Publicado: (2022)

Drug repurposing in cardiology
por: van Driel, B. O., et al.
Publicado: (2020)

Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy
por: Fluechter, Stephan, et al.
Publicado: (2010)

FHL2 expression and variants in hypertrophic cardiomyopathy
por: Friedrich, Felix W., et al.
Publicado: (2014)

Translational investigation of electrophysiology in hypertrophic cardiomyopathy
por: Flenner, Frederik, et al.
Publicado: (2021)

MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy
por: McNamara, James W., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gpi3fr2neb4jnpgdtfdt5df9oh